Santhera Pharmaceuticals

Historical price data

Santhera Pharmaceuticals is a Swiss public company with a focused mission to develop and commercialize treatments for rare neuromuscular diseases, exemplified by its long-term dedication to Duchenne muscular dystrophy (DMD). The company's strategy centers on identifying and advancing compounds that address specific pathological mechanisms in these high-need areas. While historically involved with the FDA-approved drug vamorolone for DMD, Santhera's current pipeline and strategic direction emphasize its ongoing commitment to this challenging therapeutic space.

Disease-area focused platform centered on deep expertise in the pathophysiology of rare neuromuscular disorders, guiding the identification and development of small molecule compounds targeting specific mechanisms like inflammation and mitochondrial dysfunction.

Santhera competes in the crowded DMD space against companies like Sarepta Therapeutics, PTC Therapeutics, and NS Pharma, as well as the entrenched use of corticosteroids. In the broader neuromuscular field, it faces competition from large pharma and biotech firms pursuing advanced modalities like gene therapy. Its competitive edge is deep niche expertise and agility.